Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution.

We performed immunohistochemical analysis for KIT in 365 soft tissue sarcomas. Most tumors evaluated were completely negative for KIT, including all cases of leiomyosarcoma, rhabdomyosarcoma, myxofibrosarcoma, liposarcoma, solitary fibrous tumor, synovial sarcoma, dermatofibrosarcoma protuberans, schwannoma, malignant peripheral nerve sheath tumor, clear cell sarcoma, low-grade endometrial stromal sarcoma, and follicular dendritic cell sarcoma. Tumors showing occasional immunoreactivity for KIT included extraskeletal myxoid chondrosarcoma (2/20), Ewing sarcoma/malignant primitive peripheral neuroectodermal tumor (4/20), melanotic schwannoma (3/5), metastatic melanoma (4/20), and angiosarcoma (5/20). In most cases, staining for KIT was focal. Rare tumor cells showing KIT positivity were identified in a small number of other tumors. This study demonstrates very limited expression of KIT in soft tissue tumors other than gastrointestinal stromal tumors and underscores the discriminatory value of KIT immunohistochemical analysis for differential diagnosis. As some of these findings differ markedly from previous reports, it is evident again that variations in immunohistochemical technique can lead to major discrepancies in positive staining. Since treatment eligibility for selective tyrosine kinase inhibitors such as STI571 hinges on positive immunostaining, standardization and reproducibility of meaningful results are critically important.

[1]  T. Seito,et al.  Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues , 2004, Virchows Archiv.

[2]  J. Goldblum,et al.  Enzinger and Weiss's Soft Tissue Tumors , 2001 .

[3]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[4]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[5]  M. Miettinen Are desmoid tumors kit positive? , 2001, The American journal of surgical pathology.

[6]  P. Lollini,et al.  The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. , 2000, The American journal of pathology.

[7]  L. Sobin,et al.  Gastrointestinal Stromal Tumors and Leiomyosarcomas in the Colon: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases , 2000, The American journal of surgical pathology.

[8]  L. Sobin,et al.  Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. , 2000, The American journal of pathology.

[9]  L. Sobin,et al.  Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT) , 2000, Modern Pathology.

[10]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[11]  C. Compton,et al.  Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. , 2000, The American journal of surgical pathology.

[12]  J. Lasota,et al.  KIT Expression in Angiosarcomas and Fetal Endothelial Cells: Lack of Mutations of Exon 11 and Exon 17 of C-kit , 2000, Modern Pathology.

[13]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[14]  K. Chorneyko,et al.  Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. , 1999, The American journal of surgical pathology.

[15]  C. Marshall,et al.  Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors , 1999, Oncogene.

[16]  J. Lasota,et al.  Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.

[17]  M. Tainsky,et al.  Loss of AP‐2 results in downregulation of c‐KIT and enhancement of melanoma tumorigenicity and metastasis , 1998, The EMBO journal.

[18]  A. Kovatich,et al.  CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[19]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[20]  D. Arber,et al.  Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. , 1998, Human pathology.

[21]  G. Basso,et al.  c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. , 1998, Blood.

[22]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[23]  D. Elder,et al.  Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[24]  D. McConkey,et al.  Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. , 1996, Oncogene.

[25]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[26]  John Malysz,et al.  W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity , 1995, Nature.

[27]  S. Nishikawa,et al.  Requirement of c-kit for development of intestinal pacemaker system. , 1992, Development.